在全球范围内，子宫内膜癌（Endometrial Cancer，EC）成为发达国家最常见的妇科恶性肿瘤之一，其发病率正持续攀升，严重威胁着女性健康。尽管早期EC患者经过手术治疗后的5年生存率可高达80%至90%，但若肿瘤扩散至局部或远处，其生存率会骤降至68%及17%。为了改善这一状况，迫切需要探索新的诊疗策略。

This has been linked to lifestyle changes, metabolic diseases, and obesity, with cases increasingly being reported in women ...

"The lack of a significant link between AmygA and LN metastasis in premenopausal women suggests that menopausal status may ...

The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial ...

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...

The risk and incidence of cancer among people under 50 is also on the rise, according to American Cancer Society.

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

More testing is needed, but if the same results are seen in humans, it could transform treatment of the disease.

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

Uterine manipulation with an intrauterine device is the surgical method used for early-stage cervical cancer. In this study, ...